By Josh White
Date: Wednesday 22 Apr 2026
(Sharecast News) - hVIVO said on Wednesday that it has secured a contract to conduct what it described as the world's first pivotal phase three human challenge trial for a whooping cough vaccine, marking its largest study to date.
The AIM-traded group said it would run the trial for ILiAD Biotechnologies'...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news